Budget and appropriations for domestic HIV and hepatitis prevention through the CDC and HIV treatment through HRSA; authorizing legislation and Executive Branch programs to support access to HIV prevention medication, treatment, and testing services and viral hepatitis treatment and testing services; and legislation and Executive Branch programs impacting patient access to affordable healthcare and prescription drugs offered through Medicaid, Medicare, and the private insurance market.
2025 · 3rd Quarter (July 1 - Sep 30)
HIV AND HEPATITIS POLICY INSTITUTE
Filed by HIV AND HEPATITIS POLICY INSTITUTE.
Open official filingSource-reported fields
Filing overview
- Type
- Registration
- Posted
- Sep 29, 2025
- Income
- Not reported
- Expenses
- Not reported
- Registrant
- HIV AND HEPATITIS POLICY INSTITUTE
- Filing UUID
- 4233f313-cd30-496e-904e-c42ec204b471
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Budget and appropriations for domestic HIV and hepatitis prevention through the CDC and HIV treatment through HRSA; authorizing legislation and Executive Branch programs to support access to HIV prevention medication, treatment, and testing services and viral hepatitis treatment and testing services; and legislation and Executive Branch programs impacting patient access to affordable healthcare and prescription drugs offered through Medicaid, Medicare, and the private insurance market.
Budget and appropriations for domestic HIV and hepatitis prevention through the CDC and HIV treatment through HRSA; authorizing legislation and Executive Branch programs to support access to HIV prevention medication, treatment, and testing services and viral hepatitis treatment and testing services; and legislation and Executive Branch programs impacting patient access to affordable healthcare and prescription drugs offered through Medicaid, Medicare, and the private insurance market.
Budget and appropriations for domestic HIV and hepatitis prevention through the CDC and HIV treatment through HRSA; authorizing legislation and Executive Branch programs to support access to HIV prevention medication, treatment, and testing services and viral hepatitis treatment and testing services; and legislation and Executive Branch programs impacting patient access to affordable healthcare and prescription drugs offered through Medicaid, Medicare, and the private insurance market.
Budget and appropriations for domestic HIV and hepatitis prevention through the CDC and HIV treatment through HRSA; authorizing legislation and Executive Branch programs to support access to HIV prevention medication, treatment, and testing services and viral hepatitis treatment and testing services; and legislation and Executive Branch programs impacting patient access to affordable healthcare and prescription drugs offered through Medicaid, Medicare, and the private insurance market.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.